Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA). Biogen will have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171219006245/en/
“We are pleased to extend our collaboration with our valued colleagues at Ionis, which we believe complements our ongoing efforts to enhance and build a portfolio of treatments for SMA,” stated Michel Vounatsos, chief executive officer at Biogen. “Consistent with our commitment to individuals with SMA and their families, our aim is to increase therapeutic options available for this devastating neuromuscular disease.”
“Biogen has been a great collaborator, and we share in their focus to continue to work to bring new, innovative therapies to treat SMA. We owe it to the individuals and families challenged by SMA to discover additional therapies,” said Stanley T. Crooke, M.D., Ph.D., chief executive officer and chairman of Ionis. “Our antisense technology uniquely positions us to work with Biogen towards delivering new therapies and expanding our experience in SMA.”
Under the new collaboration agreement, Ionis will receive a $25 million upfront payment and will earn development and regulatory milestone payments from Biogen if new drugs advance towards marketing approval. Upon commercialization, Biogen will pay Ionis performance milestones and tiered royalties on net sales.
Spinal Muscular Atrophy (SMA) is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in severe and progressive muscular atrophy and weakness. Ultimately, individuals with the most severe type of SMA can become paralyzed and have difficulty performing the basic functions of life, like breathing and swallowing.
Due to a loss of, or defect in the SMN1 gene, people with SMA do not produce enough survival motor neuron (SMN) protein, which is critical for the maintenance of motor neurons. The severity of SMA correlates with the amount of SMN protein. People with Type 1 SMA, the type that requires the most intensive and supportive care, produce very little SMN protein and do not achieve the ability to sit without support or live beyond two years without respiratory support. People with Type 2 and Type 3 produce greater amounts of SMN protein and have less severe, but still life-altering, forms of SMA.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 as one of the world’s first global biotechnology companies by Charles Weissman, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in global markets for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen, an antisense drug Ionis is developing to treat patients with TTR amyloidosis, and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Volanesorsen filings for marketing approval have been submitted in the U.S., EU and Canada. Inotersen is progressing toward regulatory filings for marketing authorization. Ionis' patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at www.ionispharma.com.
BIOGEN SAFE HARBOR
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 relating to the potential benefits and results that may be achieved through Biogen’s collaboration agreement with Ionis, risks and uncertainties associated with drug development and commercialization, and the potential of Biogen’s commercial business and pipeline programs, including potential new antisense oligonucleotide drug candidates for the treatment of SMA . These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation: uncertainty as to whether the anticipated benefits and potential of Biogen’s collaboration agreement with Ionis can be achieved; risks of unexpected costs or delays; uncertainty of success in the development and potential commercialization of new antisense oligonucleotide drug candidates for the treatment of SMA, which may be impacted by, among other things, the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of Biogen’s drug candidates; Biogen may encounter other unexpected hurdles which may be impacted by, among other things, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions, or failure to protect intellectual property and other proprietary rights; product liability claims; or third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen’s expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this press release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise.
IONIS’ FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements Ionis' collaboration agreement with Biogen. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended December 31, 2016, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from Ionis.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc. SPINRAZA® is a registered trademark of Biogen.
1. Darras B, Markowitz J, Monani U, De Vivo D. Chapter 8 - Spinal Muscular Atrophies. In: Vivo BTD, ed. Neuromuscular Disorders of Infancy, Childhood, and Adolescence (Second Edition). San Diego: Academic Press; 2015:117-145.
2. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell.1995;80(1):155-165.
3. Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4(1):20-26.
4. Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999;8(7):1177-1183.
5. Peeters K, Chamova T, Jordanova A. Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies. Brain.2014;137(Pt 11):2879-2896.
Matt Fearer, +1 781-464-3260
D. Wade Walke, Ph.D., 760-603-2741
Vice President, Corporate Communications and Investor Relations
Ben Strain, +1 781-464-2442
D. Wade Walke, Ph.D., 760-603-2741
Vice President, Corporate Communications and Investor Relations
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cryptos Fund, a Quasi-ETF, Is Now Open to Investors23.1.2018 09:00 | Pressemelding
Cryptos Fund allows investors to gain exposure to Cryptocurrencies with reduced risk in a regulated environment. Cryptos Fund is the brainchild of a team of leading academics, quants and security experts based in Zug, Switzerland. It is designed to passively track the CCI30 index (www.cci30.com), an indicator of cryptocurrencies valuations and the benchmark for the sector. Carlo Scevola, one of the fund’s principals, says: “Cryptos Fund was initially created as a private investment vehicle. I first bought Bitcoin in 2011, and when its value became substantial I wanted to diversify into other cryptocurrencies with a rigorous scientific approach. There was no suitable option available, so I created my own fund.” Cryptos Fund is also a response to heavy investor demand: “It bridges the gap between the traditional financial system and the cryptocurrencies sector. Investors need to participate in the cryptocurrency market via a regulated entity, which didn’t exist until now.” Cryptos Fund i
HYCM Launches Ripple and Bitcoin Cash Cryptocurrency CFDs23.1.2018 08:48 | Pressemelding
HYCM, a multi-regulated global leader in online capital markets trading, has launched trading on two additional cryptocurrencies, Ripple and Bitcoin Cash, adding XRP/USD and BCH/USD to its range of cryptocurrency offerings. The decision to add Ripple and Bitcoin Cash to its existing crypto offerings, Bitcoin, Litecoin and Ethereum, follows the continued increase in demand from investors in the wake of the recent cryptocurrency boom. HYCM thus now offers 24/5 leveraged trading on the most volatile virtual currencies coupled with low spreads and competitive margins. Ripple (XRP) is both a transaction network and crypto token which was created in 2012 as the go-to cryptocurrency for banks and global money transfers, and has recently experienced a period of growth. Bitcoin Cash (BCH) meanwhile, is a blockchain derived from the Bitcoin blockchain which followed the split of Bitcoin (hard fork) in August 2017. Bitcoin Cash has also recently experienced gains as investors seek to diversify th
ADOIT 8.3 Unboxed: BOC Group Releases the Next Version of Its Professional EA Suite23.1.2018 08:00 | Pressemelding
BOC Group is happy to present the next release of ADOIT. Powerful workflow capabilities to manage ever-changing Enterprise Architectures are one, yet not the only, highlight of ADOIT 8.3. BOC Group, an internationally leading vendor and manufacturer of software tools for globally recognized management approaches introduces the next evolution of its powerful 100% web-based EA suite. ADOIT steps out of the box and delivers valuable insights that are easily digested by decision makers through its powerful aggregated views. The EA suite enables to quickly launch Enterprise Architecture and IT Management initiatives and start turning buried or hidden information into business value with easy analysis, just a few clicks away. In the course of delivering more than 1,000 implementation projects worldwide, BOC Group has acquired extensive experience that has benefited ADOIT's development significantly. With the new workflow capabilities and release state filter options in ADOIT 8.3, on top of o
21st Century Fox Welcomes the CMA’s Provisional Finding on Company’s Genuine Commitment to Broadcasting Standards23.1.2018 07:29 | Pressemelding
21st Century Fox notes today’s publication by the Competition and Markets Authority (CMA) of its Provisional Findings Report regarding the Company’s proposed acquisition of the remaining shares in Sky. Today’s provisional findings move our proposed Sky transaction forward to the next phase of the regulatory review process. We welcome the CMA’s provisional finding that the Company has a genuine commitment to broadcasting standards and the transaction would not be against the public interest in this respect. Regarding plurality, we are disappointed by the CMA’s provisional findings. We will continue to engage with the CMA ahead of the publication of the final report in May. We also note that the CMA has elected to avail itself of the statutory 8-week extension, moving its deadline for a final decision to May 1, 2018. We anticipate regulatory approval of the transaction by June 30, 2018. About 21st Century Fox 21st Century Fox is one of the world's leading portfolios of cable, broadcast,
IDEMIA Announces Acquisition of Otono Networks and Its eSIM Orchestration Solution23.1.2018 06:30 | Pressemelding
IDEMIA, the global leader in Augmented Identity for an increasingly digital world, today announced the acquisition of Otono Networks and its industry-leading eSIM orchestration technology. Together, IDEMIA and Otono will offer a comprehensive eSIM lifecycle management solution to simplify the adoption of eSIM for both mobile operators (MNOs) and device manufacturers (OEMs). This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122006566/en/ This acquisition marks the first external expansion by the IDEMIA group, formed in 2017 when OT (Oberthur Technologies) and Safran Identity & Security (Morpho) joined forces, and illustrates IDEMIA’s strategic vision facing the future of connected devices. By 2020, connected objects in use worldwide could reach 20.4 billion (source: www.gartner.com). Faced with the increasing number of new eSIM devices (smartphones, smartwatches, tablets, PCs, etc.) and IoT applications, MNOs and OEMs must con
Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year23.1.2018 06:30 | Pressemelding
Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights as one of the 2018 Global 100 Most Sustainable Corporations in the World (Global 100) for the third consecutive year. This distinction is based on 17 key performance indicators including financial management, clean revenue, and supplier performance. Takeda performed in the top 25% on innovation capacity, receiving notable recognition for its leadership diversity. Global 100 companies in 2018 represent the top 1.3% in the world on sustainability performance. The Index launched in 2005; results are disclosed annually at the World Economic Forum in Davos. As a LEAD company within the United Nations Global Compact, Takeda’s established track record in sustainability is guided by long-term international targets such as the Sustainable Development Goals (SDGs). Takeda is the only Japanese pharmaceutical company and among the four companies from Japan to make the final 100 in 2018, and one
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom